Laboratory Genetics in Minnesota

2007 Publications from the Cytogenetics Laboratory

Full Publications for 2007:

Adeyinka A, Smoley S, Fink S, Sanchez J, Van Dyke DL, Dewald GW: Isochromosome (X)(p10) in hematologic disorders: Fluorescence in situ hybridization study of 14 new cases show three types of centromere signal patterns. Cancer Genetics and Cytogenetics 179: 25-30, 2007.

Bowen D, Call T, Jenkins G, Zent C, Schwager S, Van Dyke DL, Jelinek D, Kay N, Shanafelt T. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 48(12): 2412-7, 18067017, 2007 Dec.

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin1 TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM: Expression of TCL-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia. Leukemia Research 31(12):1737-40, 2007.

Bryce AH, Ketterling RP, Gertz MA, Kyle RA, Lust JA, Fonseca R, Lacy M, Greipp PR, Witzig TA, Rajkumar S, Dispenzieri A. POEMS syndrome, or osteosclerotic myeloma, is an uncommon plasma cell disorder associated with Peripheral neuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes, as well as bone lesions, Castlemans disease, and edema. Mod Pathol 2007 May; 20(5):592-603.

Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS.: Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology 25: 793-798, 2007.

Ganget N, Tefferi A, Pardanani A, Strand J, Lasho T, Finke CM, Knudson R, Li CY, Ketterling RP. Cytogenetic studies at diagnosis is polycythemia Vera: Clinical and JAK2V617F allele burden correlates. European Jour of Haemat. [Accepted].

Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC.: Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology 25: 799-804, 2007.

Highsmith Jr WE, Meyer KJ, Marley VM, Jenkins RB. Conversion technology for the separation of maternal and paternal copies of any autosomal chromosome in somatic cell hybrids. Current Protocols for Human Genetics. 2007 Oct Sup(55): 3.6.1-38.

Hodge JC, Lawson-Yuen A, Stoler JM, Ligon AH. Molecular studies of segmental aneusomy: FISHing for the atypical cry in del(5)(p15.3).Cytogenet Genome Res. 2007;119(1-2):15-20. Epub 2007 Dec 14. PMID: 18160776 [PubMed - indexed for MEDLINE]

Hussein K, Ketterling R, Hulshizer R, Kuffel D, Wiktor A, Hanson C, Tefferi A, Van Dyke DL: Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis. Eur J Haematol.:18088399, 2007 Dec 18 [Epub ahead of print].

Ida C, Rolig K, Hulshizer R, Van Dyke DL, Randolph J, Jenkins R, Nascimento A, Oliveira A. Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality. Cancer Genet Cytogenet 177(2):139-142, 17632782, 2007 Sep.

Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC: Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 109: 405-411, 2007.

Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A. Clinical correlates of KAK2V617F allele burden in essential thrombocythemia. Cancer 2007 Jun 1; 109(11):2279-84.

Knudson RA, Shearer BM, Ketterling RP. Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. Cancer Gen and Cyto 2007 Jan; 175:8-18.

Kreuziger L, Porcher J, Ketterling RP, Steensma D. An MLL-SEPT9 fusion and t(11;17)(q23;q25) Associated with De Novo Myelodysplastic Syndrome. Leuk Res 2007 Jan 22; [Epub ahead of print].

Kuffel DF, Carlson AW, Stupca PJ, Jalal SM. Training Guide for Chromosome Recognition. J Assoc Genetic Technol 33(2): 62-68, 2007.

Landstrom A, Knudson R, Dewald G, Ketterling RP, Tefferi A. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome. Leuk Lymphoma 2007 Nov; 48(11):2137-40.

Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD. Central neurocytoma: Management recommendations based on A 35-year experience. Int J Radiat Oncol Biol Phys 2007 Jan; 67(4):1145-1154 .

Macarenco RS, Erickson-Johnson M, Wang XK, Jenkins RB, Nascimento AG, Oliveira AM. Cytogenetic and molecular cytogenetic findings in dedifferentiated liposarcoma with neutral-like whorling pattern and metaplastic bone formation. Cancer Genet Cytogenet 2007 Jan 15; 172(2):147-50.

Mahlum E, Mandal D, Halder C, Maran A, Yaszemski MJ, Jenkins RB, Bolander ME, Sarker G. Engineering a noncarrier to a highly effective carrier peptide for noncovalently delivering biologically active proteins into human cells. Anal Biochem 2007 Hen 15; 365(2): 215-21.

Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, Davis F, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lai R, Lau C, McCarthy B, Nielsen H, Olson SH, Sadetzki S, Shete S, Wiklund F, Wrensch M, Yang P, Bondy M. GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1730-4. Review. PMID: 17855690 [PubMed - indexed for MEDLINE].

Mandal D, Srivastava A, Mahlum E, Desai D,Maran A, Yaszemski M, Jalal SM, Gitelis S, Bertoni F, Damron T, Irwin R, O'Connor M, Schwartz H, Bolander ME, Sarkar G. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 386:131-138, 2007.

Merritt JL, Zou Y, Jalal SM, Michels VV. Delineation of the cryptic 1qter deletion phenotype. Am J Med Genet A 143(6):599-603, 2007.

Micale M, Schran D, Emch S, Kurczynski T, Rahman N, Van Dyke DL. Mosaic variegated aneuploidy without microcephaly: Implications for cytogenetic diagnosis. Am J Med Genetic A.: 17632782, 2007 July 13 [Epub ahead of print].

Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW: . Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood109: 3189-3197, 2007.

Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen S, Peterson LC: Chronic lymphocytic leukemia FISH panel: impact on diagnosis. American Journal of Clinical Pathology 128: 323-32, 2007.

Northup J, Griffis K, Hawkins J, Lockhart L & Velagaleti GVN: Unusual pseudo dicentric, psu dic (1;19)(q10;q13.42), in a female with premature ovarian failure. Fertil Steril 87(3):697.e5-8, 2007.

Northup JK, Gadre SA, Ge Y, Lockhart LH, & Velagaleti GVN: Do cytogenetic abnormalities precede morphological abnormalities in a developing malignant condition? Eur J Haematol 78(2):152-156, 2007.

Ocio EM, Schop RFJ, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 136:80-86, 2007.

Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending JAK2V617F and MPLW515 mutation analysis to single hematopoietic colonies and B- and T- lymphocytes. Stem Cells 2007 Sep; 25(9):2358-62.

Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Vlodavsky E, Schooley A, Rudzinskiy P, Landolphi J. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): A clinicopathologic immunohistochemical, and fluorescence in situ hybridization study. AM J Surg Pathol 2007 Mar; 31(3):351-62.

Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, O'Neill BP, James CD, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol [in eprint].

Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A: Chromosome 5q deletion: Specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leukemia Research 2007, doi:10.1016/j.leukres.2007.07.007.

Sathanoori M, Hu J, Murthy V, Byrnes A, Vockley J, Safier R, Bedoyan J, Jalal SM, Huber H, Surti U. Cryptic duplication of 12q24.33 ® qter in a child with Angelman syndrome-simultaneous occurrence of two unrelated cytogenetic events. Am J Med Genet A 143(9):985-994, 2007.

Schubert BA, Meilinger CA, Anderson MA, Meyer KJ, Spurbeck JL, Stupca PJ, Jalal SM. Chromosome Spreading is a Function of Time and Temperature of Hypotonic Solution. J Assoc Genetic Technol 33 (4): 178-182, 2007.

Shearer BM, Thorland EC, Gonzales PR, Ketterling RP. Evaluation of a commercially available focused aCGH platform for the detection of constitutional chromosome anomalies. Am J Med Genet 2007 Oct 15;143(20):2357-70.

Smoley SA, Fink SR, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW: Frequency, hematopathology and detection of a new isodicentric variant of deletion 20q. Cancer Genetics and cytogenetics 173: 144-149, 2007.

Stevens R, Almanaseer I, Gonzalez M, Caglar D, Knudson RA, Ketterling RP, Schrock D, Seemayer TA, Bridge JA. Analysis of HER-2 Gene Amplification Using an Automated FISH Signal Enumeration System. J Mol Diagn 2007 Apr;9(2):144-50.

Sukov WR, Cheville JC, Carlson AW, Shearer BM, Piatigorsky E, Grogg KL, Sebo TJ, Sinnwell J, Ketterling RP. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 2007 May;20(5):592-603.

Tallman MS, Dewald G, Lazarus HM, Gandham S, Logan B, Rowe JM, Litzow MR, Keating A, Mehta J, Wetzler M, Pedersen T, Weisdorf DJ: Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110:409-417, 2007.

Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)- associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007 Aug; 21(8):1827-8. [Epub 2007-04-26].

Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N, Pardanani A, Hanson CA, Ketterling RP. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007 Sep; 21(9): 2074-5.

Thorland EC, Gonzalez PR, Gliem TJ, Wiktor AE, Ketterling RP. Comprehensive validation of array comparative genomic hybridization platforms: how much is enough? Genetics in Med 2007 Sept 9(9); 632-41.

Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. "Idiopathic" Eosinophilia with an Occult T-Cell Clone: Prevalence and Clinical Course. Leuk Res 2007 May 31; 31(5):691-4.

Van Dyke DL, Ebrahim S, Al Saadi A, Powell S, Zenger-Hain J, Micale M, Wiktor A, Zou S. The impact of maternal serum screening programs for Down syndrome in southeast Michigan, 1988-2003. Prenat Diagn 27 (6):583-584, 2007.

Vance GH, Kim H, Hicks G, Cherry A, Higgins R, Hulshizer R, Tallman MS, Fernandez HF, Dewald GW. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) Clinical Trial (E1900). Leukemia Research 31: 605-609, 2007.

Vencio EF, Jenkins RB, Schiller JL, Huynh TVT, Wenger DD, Inwards CY, Oliveira AM. Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol 2007 Feb; 31(2):319-21.

Wang Z, Velagaleti GVN, Eltorky MA, Tang WW, Hawkins H, Jones EA & Qiu S: Cytogenetic and molecular studies of an unusual case of multiple primary alveolar rhabdomyosarcomas: low-level chromosomal instability and reciprocal translocation t(6;11). Exp Mol Pathol 82(1):58-62, 2007.

Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, Rao KW, Rao PN, Association for Molecular Pathology Clinical Practice Committee, American College of Medical Genetics Laboratory Quality Assurance Committee. Guidance for fluorescence in situ hybridization testing in hematologic disorders. Journal of Molecular Diagnostics 9:134-43, 2007.

Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW: Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leukemia Research 31: 1193-1197, 2007.

Zou YS, Van Dyke DL, Ellison JW. Microarray comparative genomic hybridization and FISH studies of an unbalanced cryptic telomeric 2p deletion/16q duplication in a patient with mental retardation and behavioral problems. Am J Med Genet 143A:746-51, 2007.

Abstracts for 2007:

Bayerl MG, Edmonston T, Abou-Elella A, Powel J, Ketterling RP. Chronic Eosinophilic Leukemia, Molecular and Genetic Correlation. Workshop of the Society for Hematopathology and European Association for Haematopathology: Myeloid Neoplasms and Mastocytosis. Indianapolis, IN. November 1-3, 2007.

Bowen DA, Call TG, Jenkins G, Zent CS, Schwager S, Van Dyke D, Jelinek D, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed CLL including those with unfavorable cytogenetic features. XII International Workshop on CLL, London, UK, September 2007.

Champaigne NL, Laird N, Northup JK, & Velagaleti GVN: Molecular cytogenetic characterization of an interstitial de novo 13q deletion in a 3-month old with severe gastroesophageal reflux. Am J Hum Genet. #1681, p331, 2007.

Fields K, Nacionales M, Dahl R, Jalal S. Sister chromatid exchange rates do not increase in obligate carriers of Bloom syndrome. Association of Genetic Technologists Annual Meeting, Denver, CO,2007.

Hanson CA, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, Zou Y, Van Dyke DL, Ketterling RP: Trisomy 15: a clonal chromosomal abnormality with no apparent hematologic significance. United States and Canadian Academy of Pathology Annual Meeting, San Diego, CA, March 2007.

Hutchens C, Mahaffey V, Allmer D, Dahl R, Allen J, Jalal S. Mayo Clinic experience of Mitomycin C stress test over 10-year period for diagnosis of Fanconi anemia. Association of Genetic Technologists Annual Meeting, Denver, CO, 2007.

Jenkins RB, Nakagawa T, Kollmeyer T, Morlan B, Berstrahl-Davis B, Cheville J, Klee G, Ballman KV. A tissue biomarker panel that predicts which men with a rising PSA post-definitive prostate cancer therapy will have systemic progression. (Submitted for ASCO 2007 Annual Meeting June 1-5, 2007).

Kempin S, Kay NE, Sun Z, Secreto C, Tschumper R, Jelinek D, Smoley S, Van Dyke D, Salzman J, Tallman M, Rosen S. Early results of Pentostatin, Cytoxan, Rituximab (PCR) followed by CAMPATH-H (CA) for the treatment of relapse/refractory chronic lymphocytic leukemia (CLL) in ECOG trial 2903. American Society of Hematology, Atlanta, GA, December 2007.

Kulharya AS, Flannery DB, Norris K, Lovell CM, Levy B & Velagaleti GVN: Fine breakpoint mapping using Affymetrix human mapping 500K array of two unrelated patients with rare de novo overlapping interstitial deletions of chromosome 9q. Am J Human Genet. #1626, p 322, 2007.

Landstrom A, Ketterling R, Knudson R, Dewald G, Tefferi A. Philadelphia chromosome mosaicism due to additional cytogenetic abnormalities in chronic myeloid leukemia might adversely affect prognosis and response to imatinib. J Investig Med 2007 Mar; 55(2 Suppl S):S349.

Leslein NS, Keefe JG, Rubin De Celis C, Abubakr Y, Thorland EC, Ketterling RP. Identification of 2 leukemia patients with a constitutional microdeletion of the MYH11 gene region at 16q13.1; mapping by bacs and caution for the inv(16) FISH testing in AML patients. (AGT).

List AF, Wride K, Dewald GW, Bennett JM, Giagounidis A, Kurtin S, Knight RD. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 2007 May; 31(Suppl 1):S38.

Mahaffey VJ, Van Dyke DL. Managing a cytogenetics laboratory using workload recording. Association of Genetic Technologists Annual Meeting, Denver, CO, May 2007.

Moorman A, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia. Haematologica 2007 Jun; 92(Suppl 1):139.

Nacionales M, Bloxham M, James C, Jalal S. Automated metaphase harvester and manual harvest techniques: a comparison study. Association of Genetic Technologists Annual Meeting, Denver, CO, 2007.

Nowakowski GS, Smoley S, Schwager S, Zent CS, Call TG, Shanafelt TD, Hanson C, Tschumper RC, Jelinek DF, Van Dyke DL, Kay NE. Presence of immunoglobulin heavy chain gene (IGH) translocations in chronic lymphocytic leukemia is related to poor prognosis. American Society of Hematology, Atlanta, GA, December 2007.

Rassenti LZ, Huynh L, Basak GW, Chia E, Van Dyke D, Heerema N, Zahrieh D, Dal Cin P, Dell'Aquila ML, Koduru P, Byrd JC, Kay NE, Rai KR, Brown JR, Wierda WG, Greaves AW, Croce CM, Kipps TJ. TCL1 expression in chronic lymphocytic leukemia correlates with the intensity of 11q deletions and ZAP-70. American Society of Hematology, Atlanta, GA, December 2007.

Rassenti LZ, Van Dyke, D, Heerema N, Zahrieh D, Dal Cin P, Dell'Aquila ML, Koduru P, Byrd JC, Kay NE, Rai KR, Brown JR, Wierda WG, Greaves AW, Neuberg DS, Kipps TJ. Correlations of genomic aberrations and prognostic markers in chronic lymphocytic leukemia in relation to the intensity of the clonal abnormality. American Society of Hematology, Atlanta, GA, December 2007.

Remstein ED, Law ME, Dewald GW, Kurtin PJ, Dogan A. CPG oligonucleoticles induce growth of malt lymphoma cells in vitro and reveal novel cytogenetic abnormalities. Laboratory Investigation 2007 Mar; 87 (Suppl 1): 257A-8A.

Schooley AC, Knudson RA, Ketterling RP. Validation of PML/RARA dual color double fusion (D-FISH) probes on the Bioview™ Duet automated dot counting system: application to FISH minimal residual disease testing. (AGT).

Sidhu JS, Bellina DP, Ketterling RP. Myelodysplastic syndrome. (Accepted, oral presentation, Society for Hematopathology).

Sukov WR, Carlson AW, Shearer BM, Grogg KL, Cheville JC, Ketterling RP. Inflammatory myofibroblastic tumor of urinary bladder: Immunohistochemical, molecular, and cytogenetic characterization and comparision. Mod Pathol 2007 Mar; 20(Suppl 2):178A.

Van Dyke DL, Dewald GW, Call TG, Jelinek DF, Zent CS, Shanafelt TD, Smoley SA, Stockero KJ, Kay NE. Deletion 13q in B-CLL: interphase FISH reveals more than CpG stimulation. 49th Annual Meeting of American Society of Hematology, Atlanta, GA, December 2007.

Van Dyke DL, Dewald GW, Call TG, Jelinek DF, Zent CS, Shanafelt TD, Smoley SA, Peterson MA, Bloxham ME, Stockero KJ, Fink SR, Paternoster SF, Kay NE. Deletion 13q in B-CLL is often submicroscopic and not seen in metaphase analysis after CpG stimulation. XII International Workshop on CLL, London, UK, Poster, September 2007, Leuk Lymphoma 48(1) S146, 2007.

Velagaleti GVN, Cooke SL, Northup JK, Champaigne NL, Zinser W, Edwards PAW, & Lockhart LH: Molecular cytogenetic characterization of a unique and complex de novo 8p rearrangement. Am J Hum Genet. #1583, p314, 2007.

Wabah M, Shuttlesworth J., Northup N, Panova T, Elghetany S, Hudnall D, & Velagaleti GVN: Morphologically normal bone marrows with increased levels of cytogenetically abnormal cells may represent early embryonic stem cells. Arch Pathol Lab Med. 131: p1420, 2007.

Zou YS, Sarkar G, Dawson DB, Halder C, Schowalter D, Jenkins RB, Jalal SM. Differential gene and phenotypic expressions in two patients with identical 22q11.2 microduplications of a 3-Mb region based on microarray and miRNA analysis. American College of Medical Genetics Annual Meeting, Nashville, TN, 2007.

Non Peer-Reviewed Published Articles for 2007:

Hodge JC and Morton CC. Genetic heterogeneity among uterine leiomyoma: Insights into malignant progression. Human Molecular Genetics Apr 152007;16(R1):R7-R13.